Project Details
Description
MT2025-28: Phase 1/2 open-label, first-in-human, single-agent, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics...
| Status | Active |
|---|---|
| Effective start/end date | 11/10/25 → 10/19/36 |
Funding
- SANOFI-AVENTIS US
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.